Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.
暂无分享,去创建一个
[1] S. Vollset,et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.
[2] E. Gurfinkel,et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.
[3] S. Nattel,et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. , 1997, The New England journal of medicine.
[4] B. Davis,et al. Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .
[5] J. Leavitt,et al. Emergency Department Use of Aspirin in Patients with Possible Acute Myocardial Infarction , 1997, Annals of Internal Medicine.
[6] R A Schatz,et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. , 1997, The New England journal of medicine.
[7] Cristina Barlassina,et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension , 1997, The Lancet.
[8] C A Beltrami,et al. Apoptosis in the failing human heart. , 1997, The New England journal of medicine.
[9] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[10] L. Goldman,et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.
[11] L Goldman,et al. Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction , 1997 .
[12] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[13] P. Anversa,et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. , 1996, The American journal of physiology.
[14] A. Glasebrook,et al. Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.
[15] R. Lifton. Molecular Genetics of Human Blood Pressure Variation , 1996, Science.
[16] G. Gibbons,et al. Molecular Therapies for Vascular Diseases , 1996, Science.
[17] J. Breslow. Mouse Models of Atherosclerosis , 1996, Science.
[18] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[19] P. Anversa,et al. Gender differences and aging: effects on the human heart. , 1995, Journal of the American College of Cardiology.
[20] P Whelton,et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. , 1995, Hypertension.
[21] N. Maeda,et al. Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[22] Jason A. Lowry,et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. , 1995, Circulation.
[23] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[24] R. Matthews,et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.
[25] P. Ganz,et al. Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.
[26] O. H. Bing. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. , 1994, Journal of molecular and cellular cardiology.
[27] R. Lefkowitz,et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.
[28] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[29] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[30] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[31] J. Loscalzo,et al. Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.
[32] R. Pokras. Detailed diagnoses and procedures for patients discharged from short-stay hospitals. United States, 1985. , 1987, Vital and health statistics. Series 13, Data from the National Health Survey.
[33] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.
[34] M. LeWinter,et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.
[35] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .
[36] W. Kannel,et al. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.
[37] W. B. Kouwenhoven,et al. Closed chest defibrillation of the heart. , 1957, Surgery.
[38] T. Dawber,et al. Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.
[39] J. Herrick. CLINICAL FEATURES OF SUDDEN OBSTRUCTION OF THE CORONARY ARTERIES , 1912 .